NCT04412668View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

October 23, 2020

Study Completion Date

October 23, 2020

Conditions
SARS-CoV-2 (COVID-19) Severe Pneumonia
Interventions
DRUG

Efzofitimod 1 mg/kg

Concentrate for solution for infusion

DRUG

Efzofitimod 3 mg/kg

Concentrate for solution for infusion

DRUG

Placebo

Concentrate for solution for infusion

Trial Locations (10)

20010

aTyr Investigative Site, Washington D.C.

21401

Anne Arundel Medical Center, Annapolis

22042

Inova Fairfax Medical Campus, Falls Church

33125

University of Miami, Miami

35294

University of Alabama at Birmingham, Birmingham

43614

aTyr Investigative Site, Toledo

52242

University of Iowa, Iowa City

08360

aTyr Investigative Site, Vineland

00968

Alliance Medical Service, Cardio Pulmonary Research, Guaynabo

00674

Manati Medical Center, Manatí

All Listed Sponsors
lead

aTyr Pharma, Inc.

INDUSTRY

NCT04412668 - Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19 | Biotech Hunter | Biotech Hunter